FDA Approved Drugs for Urology

Drugs Approved in 2017

Imfinzi (durvalumab); AstraZeneca; For the treatment of advanced or metastatic urothelial carcinoma, Approved May 2017

Vabomere (meropenem and vaborbactam); The Medicines Company; For the treatment of complicated urinary tract infections , Approved August 2017

Drugs Approved in 2016

Tecentriq (atezolizumab); Genentech; For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer, Approved May 2016

Drugs Approved in 2015

Avycaz (ceftazidime-avibactam); Actavis; For the treatment of complicated intra-abdominal and urinary tract infections, Approved February 2015

Xuriden (uridine triacetate); Wellstat Therapeutics; For the treatment of hereditary orotic aciduria, Approved September 2015

Drugs Approved in 2014

Zerbaxa (ceftolozane + tazobactam) ; Cubist Pharmaceuticals; For the treatment of complicated intra-abdominal and urinary tract infections, Approved December 2014

Drugs Approved in 2013

Xiaflex (collagenase clostridium histolyticum); Auxilium; For the treatment of Peyronie's disease, Approved December of 2013

Xofigo (radium Ra 223 dichloride); Bayer Healthcare Pharmaceuticals; For the treatment of prostate cancer with bone metastases, Approved May 2013

Drugs Approved in 2012

Bio-T-Gel (testosterone gel); Teva Pharmaceutical; For the treatment of hypogonadism, Approved February 2012

Myrbetriq (mirabegron); Astellas Pharma US, Inc; For the treatment of overactive bladder, Approved June 2012

Stendra (avanafil); Vivus; For the treatment of erectile dysfunction, Approved April 2012

Xtandi (enzalutamide); Medivation; For the treatment of metastatic castration-resistant prostate cancer, Approved August 2012

Drugs Approved in 2011

Anturol (oxybutynin) Gel; Antares Pharma; For the treatment of overactive bladder, Approved December 2011

Zytiga (abiraterone acetate); Centocor Ortho Biotech; For the treatment of prostate cancer, Approved May 2011

Drugs Approved in 2010

Jalyn (dutasteride + tamsulosin); GlaxoSmithKline; For the treatment of benign prostatic hyperplasia, Approved June 2010

Jevtana (cabazitaxel); sanofi aventis; For the treatment of prostate cancer, Approved June 2010

Provenge (sipuleucel-T); Dendreon; For the treatment of hormone refractory prostate cancer, Approved May 2010

Drugs Approved in 2008

Degarelix (degarelix for injection); Ferring Pharmaceuticals; For the treatment of prostate cancer, Approved December of 2008

Drugs Approved in 2007

Doribax (doripenem); Johnson & Johnson; For the treatment of intra-abdominal infections and urinary tract infections, Approved October 2007

Drugs Approved in 2003

Cialis (tadalafil); Eli Lilly; Oral agent for the treatment for erectile dysfunction, Approved December 2003

Levitra (vardenafil); Bayer, GlaxoSmithKline; For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003

Plenaxis (abarelix for injectable suspension); Praecis Pharmaceuticals; For treatment of advanced prostate cancer, Approved December 2003

UroXatral (alfuzosin HCl extended-release tablets); Sanofi-aventis; For the treatment of of the signs and symptoms of benign prostatic hyperplasia, Approved June 2003

Drugs Approved in 2002

Bravelle (urofollitropin for injection, purified); Ferring Pharmaceuticals; Human-derived follicle-stimulating hormone (hFSH) for use in ovulation induction for the treatment of infertility., Approved May 2002

Eligard (leuprolide acetate); Atrix Laboratories; For the palliative treatment of advanced prostate cancer, Approved January 2002

Drugs Approved in 2001

Dutasteride; GlaxoSmithKline; For the treatment of symptomatic benign prostatic hyperplasia, Approved November 2001

Trelstar LA (triptorelin pamoate); Debiopharm; Intramuscular injection for the treatment of advanced stage prostate cancer, Approved June 2001

Drugs Approved in 2000

Ovidrel (gonadotropin, chorionic human recombinant); Serono Laboratories; For the induction of final follicular maturation and early luteinization in infertile women, Approved September 2000

Trelstar Depot (triptorelin pamoate); Debio Rechereche Pharmaceutique, Target Research Associates; For the palliative treatment of advanced prostate cancer, Approved June 2000

Viadur (leuprolide acetate implant); Alza; For pain relief in men with advanced prostate cancer, Approved March 2000

Drugs Approved in 1998

Viagra; Pfizer; Treatment for impotence, Approved March 1998

Drugs Approved in 1997

INFANRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed); SmithKline Beecham; Treatment for diphtheria, tetanus and pertussis (whooping cough) in infants and children, January 1997

EDEX; Schwarz Pharma; Treatment for erectile dysfunction, Approved June 1997

FEMSTAT One; Roche; Treatment for vaginal yeast infections, Approved Februrary 1997

FLOMAX; Boehringer Ingelheim; Treatment for benign prostatic hypertrophy (BPH), Approved October 1997

Follistim (TM) (follitropin beta for injection); Organon; Treatment for infertility, Approved September 1997

Gonal-F (follitropin alfa for injection); Serono Laboratories; Treatment for infertility, Approved September 1997

Interstim Continence Control Therapy; Medtronic; Treatment for incontinence, Approved September 1997

Lupron Depot (leuprolide acetate for depot suspension); TAP Pharmaceuticals; Treatment for prostate cancer, Approved July 1997

REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals; Generic equivalent of Pergonal, Approved February 1997

SPORANOX (itraconazole); Janssen Pharmaceuticals; Treatment for oral thrush, Approved March 1997

Drugs Approved in 1996

Eulexin (flutamide); Schering-Plough; Treatment for prostate cancer, Approved June 1996

Fertinex (urofollitropin for injection, purified); Serono Laboratories; Treatment for patients undergoing infertility treatments, Approved September 1996

Lupron Depot (leuprolide acetate for depot suspension); Abbott Laboratories; Treatment for advanced prostate cancer, Approved January 1996

Monurol; Forest Laboratories; Treatment for uncomplicated urinary tract infection, Approved December 1996

Muse; Vivus; Treatment for impotence, Approved October 1996

Zoladex (10.8 mg goserelin acetate implant); AstraZeneca; Treatment for advanced prostate cancer, Approved January 1996

Drugs Approved in 1995

Caverject (alprostadil); Upjohn; Treatment for impotence, Approved on July 6, 1995